Publications by authors named "Gregory S Cameron"

Claim this Profile
E
Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: Subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1).
Shinichi Imafuku, Hitoe Torisu-Itakura, Atsushi Nishikawa, Fangyi Zhao, Gregory S Cameron

J Dermatol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
Hidehisa Saeki, Hidemi Nakagawa, Ko Nakajo, Taeko Ishii, Yoji Morisaki, Gregory S Cameron

J Dermatol· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
Kenneth B Gordon, Andrew Blauvelt, Kim A Papp, Richard G Langley, Thomas Luger, Gregory S Cameron

N Engl J Med· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Christopher E M Griffiths, Kristian Reich, Mark Lebwohl, Peter van de Kerkhof, Carle Paul, Gregory S Cameron

Lancet· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
Kenneth B Gordon, Craig L Leonardi, Mark Lebwohl, Andrew Blauvelt, Gregory S Cameron

J Am Acad Dermatol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population exposure-response model to support dosing evaluation of ixekizumab in patients with chronic plaque psoriasis.
Lai-San Tham, Cheng-Cai Tang, Siak-Leng Choi, Julie H Satterwhite, Gregory S Cameron

J Clin Pharmacol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors.
Mark C Genovese, Maria Greenwald, Chul-Soo Cho, Alberto Berman, Ling Jin, Gregory S Cameron

Arthritis Rheumatol· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis.
James G Krueger, Scott Fretzin, Mayte Suárez-Fariñas, Patrick A Haslett, Krista M Phipps, Gregory S Cameron

J Allergy Clin Immunol· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulation of blood pressure by central melanocortinergic pathways.
Jerry R Greenfield, Jeffrey W Miller, Julia M Keogh, Elana Henning, Julie H Satterwhite, Gregory S Cameron

N Engl J Med· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis